Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 32.05 INR
Change Today +3.70 / 13.05%
Volume 450.5K
JGPH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

jagsonpal pharmaceuticals (JGPH) Snapshot

Open
29.70
Previous Close
28.35
Day High
33.75
Day Low
28.65
52 Week High
12/8/14 - 46.85
52 Week Low
09/5/14 - 19.80
Market Cap
839.6M
Average Volume 10 Days
51.5K
EPS TTM
0.45
Shares Outstanding
26.2M
EX-Date
--
P/E TM
71.7x
Dividend
0.10
Dividend Yield
1.56%
Current Stock Chart for JAGSONPAL PHARMACEUTICALS (JGPH)

Related News

No related news articles were found.

jagsonpal pharmaceuticals (JGPH) Related Businessweek News

No Related Businessweek News Found

jagsonpal pharmaceuticals (JGPH) Details

Jagsonpal Pharmaceuticals Limited develops and manufactures active pharmaceutical ingredients and formulations worldwide. The company’s active pharmaceutical ingredients (APIs) include allylestrenol, dextropropoxyphene HCL, dextropropoxyphene napsylate, disulfiram, thiopental sodium, thiopental acid, tolnaftate, and sildenafil citrate, as well as metformin HCL, BP, USP, and EP. It offers products for various therapeutic categories, such as anabolic steroids, analgesics, anesthetics, anti-allergic, anti-asthamatics, anti-cholinergic agents, anti-convulsants, anti-diabetics, anti-diarrhoeals, anti-emetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-inflammatory agents, anti-malarials, anti-nauseants, anti-protozoals, anti-pyretic, anti-rheumatic drugs, anti-spasmodic agents, and anti-septic agents. The company also offers anti-tubercular drugs, anti-ulcerants, anxiolytics, cardiovascular drugs, corticosteroids, cough syrups, diuretics, drugs for alcohol dependence, GI anti-infectives, haematinics, imaging agents, laxatives, male/female hormones, multivitamins, nutraceuticals, ophthalmic lubricants, oral rehydrating salts, sedative-hypnotics, softgels, systemic anti-infectives, throat pain spray, tonics, and uterine stimulants. Jagsonpal Pharmaceuticals Limited sells its products under the Lycored, Metadec, Maintane, Metabol, Doxypal DR, Parvon, and Indocap SR brand names. The company was founded in 1964 and is based in New Delhi, India.

Founded in 1964

jagsonpal pharmaceuticals (JGPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jagsonpal pharmaceuticals (JGPH) Key Developments

Jagsonpal Pharmaceuticals Limited Recommends Final Dividend

Jagsonpal Pharmaceuticals Limited announced that the board has recommended a final dividend of INR 0.10 per share (2%), subject To Approve the shareholders at the upcoming AGM.

JAGSONPAL Pharmaceuticals Ltd Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015

JAGSONPAL Pharmaceuticals Ltd. reported audited standalone earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 388.486 million against INR 312.808 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 9.33 million against INR 30.237 million a year ago. Loss from ordinary activities before tax was INR 0.681 million against profit from ordinary activities before tax INR 12.528 million a year ago. Net profit from ordinary activities after tax was INR 0.679 million against INR 12.220 million a year ago. Basic and diluted earnings per share (after extraordinary items) were INR 0.03 against INR 0.47 a year ago. For the year, the company reported net sales/income from operations (net of excise duty) of INR 1,381.509 million against INR 1,438.509 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 60.192 million against INR 78.525 million a year ago. Profit from ordinary activities before tax was INR 16.717 million against INR 25.313 million a year ago. Net profit from ordinary activities after was INR 11.711 million against INR 21.207 million a year ago. Basic and diluted earnings per share (after extraordinary items) were INR 0.45 against INR 0.81 a year ago.

JAGSONPAL Pharmaceuticals Ltd to Report Q4, 2015 Results on May 29, 2015

JAGSONPAL Pharmaceuticals Ltd announced that they will report Q4, 2015 results on May 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JGPH:IN 32.05 INR +3.70

JGPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JGPH.
View Industry Companies
 

Industry Analysis

JGPH

Industry Average

Valuation JGPH Industry Range
Price/Earnings 61.2x
Price/Sales 0.5x
Price/Book 0.7x
Price/Cash Flow 18.6x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAGSONPAL PHARMACEUTICALS, please visit www.jagsonpal.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.